BioSpace News Archive

Sermonix Pharmaceuticals Inc. today announced that China’s National Medical Products Administration (NMPA) approved the investigational new drug application (IND) for oral lasofoxifene (HLX78 in China) submitted with the assistance of Chinese development partner Shanghai Henlius Biotech, Inc. (2696.HK).

Agios Pharmaceuticals, Inc. today announced that the time of the company’s presentation at the Goldman Sachs 45th Annual Global Healthcare Conference has been updated to Monday, June 10, 2024 at 8:40 a.m. ET.

LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced the preliminary results for the unipolar patient cohort of the RECOVER clinical study, assessing the use of VNS Therapy™ in treatment-resistant depression.

Vanda Pharmaceuticals Inc. confirmed that it has received an unsolicited, non-binding indication of interest from Cycle Group Holdings Ltd. to acquire the Company for $8.00 per share in cash.

BioNTX, the leading biotechnology and healthcare innovation trade organization in North Texas, is thrilled to announce the much-anticipated 10th Annual iC³® Life Science & Healthcare Innovation Summit.

Lucius Partners, LLC (“LP”) today announced that its portfolio company, AerWave Medical, Inc., has treated its first two patients in its First-in-Human Trial (FIH).

Medexus Pharmaceuticals (TSX: MDP) (OTCQX: MEDXF) was informed by medac, licensor of Medexus’s commercialization rights to treosulfan, that the US Food and Drug Administration has accepted for review medac’s April 2024 resubmission of the New Drug Application for treosulfan.

Tonix Pharmaceuticals Holding Corp. today announced that it will effect a 1-for-32 reverse stock split of its outstanding common stock.

Barinthus Biotherapeutics plc (NASDAQ: BRNS), a biopharmaceutical company developing novel T cell immunotherapeutic candidates, today announced the presentation of updated data from two clinical trials in people with chronic hepatitis B (CHB) at the European Association for the Study of the Liver (EASL) Congress 2024.

In recent decades, our improved understanding of cancer has illuminated that we cannot treat all cancers as one disease - scientists have classified hundreds of types and found a myriad of genetic drivers underlying them.